This is a slow-growing form of B-cell lymphoma. About 20% to 30% of all non-Hodgkin's lymphomas are follicular lymphoma (FL). This cancer usually starts in people who are over 65. It usually grows ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

The author of the ‘Leonard List’ that highlights emerging hematologic research to be presented at annual ASH meetings is also ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Iron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression.

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.